Biocon Biologics Bolstered By Goldman Sachs Investment
Deal Worth $150m Values Biocon Subsidiary At Nearly $4bn
Goldman Sachs is investing around $150m in Biocon Biologics, valuing the Biocon subsidiary at just under $4bn.
Goldman Sachs is investing around $150m in Biocon Biologics, valuing the Biocon subsidiary at just under $4bn.